OncoMatch/Clinical Trials/NCT06759649
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
Is NCT06759649 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including COM503 and Zimberelimab for neoplasm.
Treatment: COM503 · Zimberelimab — The overall goal of this first-in-human (FIH) clinical trial is to learn about the safety and dosing of COM503 when given alone or in combination with zimberelimab in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of COM503 as monotherapy and COM503 in combination with zimberelimab in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the recommended phase 2 dose (RP2D) of COM503 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Prior therapy
Must have received: standard therapy
disease progression on or following all available standard of care (SOC) therapies known to confer clinical benefit
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Yale- New Haven Hospital- Yale Cancer Center · New Haven, Connecticut
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- START Midwest · Grand Rapids, Michigan
- The West Clinic, PLCC dba West Cancer Center · Germantown, Tennessee
- NEXT Oncology San Antonio · San Antonio, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify